Service d'hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France.
INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM 1116, CHRU de Nancy, FCRIN INI-CRCT, Université de Lorraine, Nancy, France.
Br J Haematol. 2023 Jun;201(6):1066-1071. doi: 10.1111/bjh.18754. Epub 2023 Mar 15.
This 16-month-long multicentre retrospective study of 225 allogeneic haematopoietic stem cell transplantation (alloHSCT) recipients with COVID-19 examines risk factors for severity and mortality, describing the successive waves of infections (from March to June 2020 and from August 2020 to June 2021). We confirm the negative role of low respiratory tract disease and immunosuppressive treatment. We highlight significantly lower percentages of severe forms and COVID-19-related mortality during the second wave. Monthly comparative evolution of cases in alloHSCT recipients and in the French population shows a higher number of cases in alloHSCT recipients during the first wave and a decrease from February 2021.
本研究为一项长达 16 个月的回顾性多中心研究，纳入了 225 例 COVID-19 合并异基因造血干细胞移植（alloHSCT）患者，分析了严重程度和死亡率的危险因素，描述了连续的感染波次（2020 年 3 月至 6 月和 2020 年 8 月至 2021 年 6 月）。我们证实了下呼吸道疾病和免疫抑制治疗的负面作用。我们强调了第二波感染中严重疾病形式和 COVID-19 相关死亡率的百分比显著降低。alloHSCT 受者和法国人群中病例的每月比较演变表明，第一波感染中 alloHSCT 受者的病例数更多，而从 2021 年 2 月开始则有所下降。
